Use of 2-methoxyphenyl-1-methyl-5β-methylethenyl-pyrrole-2-acetamide-acetic acid compound for the production of an anti-inflammatory drug that predicts gastric hyperplasia and renal dysfunction

摘要

The present invention relates to the use of the compound 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamido acetate (known also as amtolmetin guacyl and indicated in the present description also as MED 15) for the production of a NSAID for treating an inflammatory pathological condition with effect of prevention of NSAID-related hydrochloric acid hypersecretion, wherein in order to show its gastro-protective effect same compound has to be administered on empty stomach and without a simultaneous assumption of H1 receptor inhibiting drugs.